1例头孢哌酮舒巴坦致患者血小板减少的用药分析与药学监护  

Medication analysis and pharmaceutical care for a patient with thrombocytopenia induced by cefoperazone sulbactam

作　　者：王为[1,2] 曹爱霖 钱皎[1] WANG Wei;CAO Ai-lin;QIAN Jiao(Changhai Hospital of Shanghai,Shanghai 200433;Fourth Hospital of Wuhan,Wuhan 430030)

机构地区：[1]上海长海医院,上海200433 [2]武汉市第四医院,武汉430030

出　　处：《中南药学》2018年第9期1315-1318,共4页Central South Pharmacy

摘　　要：临床药师参与1例冠心病合并肺部感染出现血小板减少的患者诊治过程,查阅相关文献,协助医师确定致血小板减少的药物,讨论药源性血小板减少症的机制及处理措施。通过停用可疑药物,患者血小板计数恢复正常值后,顺利进行手术治疗,之后病情控制平稳,顺利出院。临床药师通过对患者进行药学监护,可协助临床及时发现并处理药物相关不良反应。在使用头孢哌酮舒巴坦治疗过程中,需严密监测血常规及凝血功能,警惕血小板减少及出血并发症的发生,尤其是有高危因素患者,以便及时对症处理。Pharmacists involved in the treatment of a patient with coronary heart disease and pulmonary infection and drug-induced thrombocytopenia and discussed the mechanism of drug-induced thrombocytopenia and treatment measures. Clinical pharmacists helped doctors to determine the causative drug. The patient＇s platelet count returned to normal after discontinuation of some suspicious drugs before the patient was successfully treated by surgery and discharged. Drug-related adverse reactions were dealt with in time via pharmaceutical. In the treatment with cefoperazone sulbactam treatment, we closely monitored the routine blood tests and coagulation function and should be vigilant of thrombocytopenia and bleeding, especially in patients with risk factors.

关 键 词：头孢哌酮舒巴坦 血小板减少 药物不良反应 药学监护 

分 类 号：R730.53[医药卫生—肿瘤]